Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.1667.

CNTX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Weiss Ratings cut Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Maxim Group lowered their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Finally, Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th.

Context Therapeutics Trading Down 4.0%

NASDAQ:CNTX opened at $0.37 on Friday. The stock has a market capitalization of $33.82 million, a PE ratio of -0.77 and a beta of 1.69. Context Therapeutics has a 1-year low of $0.34 and a 1-year high of $3.62. The firm has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $1.53.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, equities analysts predict that Context Therapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP acquired a new stake in Context Therapeutics during the 1st quarter valued at $13,755,000. Blue Owl Capital Holdings LP increased its holdings in shares of Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Context Therapeutics in the second quarter valued at $3,417,000. Seven Fleet Capital Management LP bought a new position in shares of Context Therapeutics in the first quarter valued at about $500,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Context Therapeutics in the second quarter valued at about $416,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted and immune-based treatments for solid tumors, with an emphasis on cancers that have limited treatment options. The company is headquartered in Philadelphia and conducts development activities through collaborations and clinical research networks.

Its lead investigational program is CTIM-76, a bispecific antibody designed to recognize Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.